Evanson Jeff has filed 7 insider transactions across 1 company since January 2023.
Most recent transaction: a grant/award of 25000 shares of Outlook Therapeutics, Inc. ($OTLK) on March 20, 2024.
Activity breakdown: 1 open-market purchase and 4 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 20, 2024 | Outlook Therapeutics, Inc. | $OTLK | Evanson Jeff | CHIEF COMMERCIAL OFFICER | A | Stock Option (Right to Buy) | 25000 | $0.00 | 25,000.0000 | 13,012,833 | 9999.99% | 0.19% |
| March 7, 2024 | Outlook Therapeutics, Inc. | $OTLK | Evanson Jeff | CHIEF COMMERCIAL OFFICER | P | Common Stock | 62484 | $0.42 | 808,459.0000 | 13,012,833 | 8.38% | 0.48% |
| April 17, 2023 | Outlook Therapeutics, Inc. | $OTLK | Evanson Jeff | Chief Commercial Officer | A | Stock Option (Right to Buy) | 192143 | $0.00 | 192,143.0000 | 12,833,330 | 9999.99% | 1.50% |
| Jan. 20, 2023 | Outlook Therapeutics, Inc. | $OTLK | Evanson Jeff | Chief Commercial Officer | S | Common Stock | 267000 | $1.11 | 745,975.0000 | 227,410,533 | 26.36% | 0.12% |
| Jan. 17, 2023 | Outlook Therapeutics, Inc. | $OTLK | Evanson Jeff | Chief Commercial Officer | S | Common Stock | 27162 | $1.31 | 1,149,968.0000 | 227,410,533 | 2.31% | 0.01% |
| Jan. 18, 2023 | Outlook Therapeutics, Inc. | $OTLK | Evanson Jeff | Chief Commercial Officer | S | Common Stock | 33738 | $1.25 | 1,116,230.0000 | 227,410,533 | 2.93% | 0.01% |
| Jan. 19, 2023 | Outlook Therapeutics, Inc. | $OTLK | Evanson Jeff | Chief Commercial Officer | S | Common Stock | 103255 | $1.22 | 1,012,975.0000 | 227,410,533 | 9.25% | 0.05% |